Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine

Xenobiotica

Volumn 45, Issue 2, 2015, Pages 124-130

  Uehara, Shotaro ^a,b   Murayama, Norie ^b   Nakanishi, Yasuharu ^a   Nakamura, Chika ^a   Hashizume, Takanori ^c   Zeldin, Darryl C ^d   Yamazaki, Hiroshi ^b   Uno, Yasuhiro ^a  

^a SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA OHTANI UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cynomolgus monkey; Cytochrome P450; Expression; Liver; Small intestine

Indexed keywords

ASTEMIZOLE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2A; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 4A11; CYTOCHROME P450 4F11; CYTOCHROME P450 4F12; CYTOCHROME P450 4F2; CYTOCHROME P450 4F3; EBASTINE; LAURIC ACID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HYDROXYLATION; IMMUNOBLOTTING; IMMUNOCHEMISTRY; LIVER; MACACA FASCICULARIS; MALE; NONHUMAN; PROTEIN EXPRESSION; SMALL INTESTINE; ANIMAL; ENZYMOLOGY; LIVER MICROSOME; METABOLISM; MICROSOME;

ANIMALIA; MACACA FASCICULARIS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; INTESTINE, SMALL; LIVER; MACACA FASCICULARIS; MALE; MICROSOMES; MICROSOMES, LIVER;

EID: 84919726719     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.952800     Document Type: Article

References (31)

1. Danese E, Montagnana M, Johnson JA, et al. (2012). Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther 92:746-56.
2. Edson KZ, Prasad B, Unadkat JD, et al. (2013). Cytochrome P450-dependent catabolism of vitamin K: omega-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry 52:8276-85.
3. Hashizume T, Imaoka S, Mise M, et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304.
4. Hashizume T, Mise M, Matsumoto S, et al. (2001). A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 29:798-805.
5. Hsu MH, Savas U, Griffin KJ, Johnson EF. (2007). Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev 39:515-38.
6. Jin Y, Zollinger M, Borell H, et al. (2011). CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos 39: 191-8.
7. Kalsotra A, Strobel HW. (2006). Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol Ther 112: 589-611.
8. King LM, Ma J, Srettabunjong S, et al. (2002). Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 61: 840-52.
9. Liu KH, Kim MG, Lee DJ, et al. (2006). Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34:1793-7.
10. Matsumoto S, Hirama T, Matsubara T, et al. (2002). Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:1240-5.
11. McDonald MG, Rieder MJ, Nakano M, et al. (2009). CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75:1337-46.
12. Michaels S, Wang MZ. (2014). The revised human liver cytochrome P450 ''pie'': absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos 42:1241-51.
13. Nakamura K, Obayashi K, Araki T, et al. (2012). CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther 37:481-5.
14. Nelson DR, Zeldin DC, Hoffman SM, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
15. Nishimuta H, Sato K, Mizuki Y, et al. (2011). Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab Pharmacokinet 26: 300-6.
16. Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-8.
17. Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 ''pie''. Drug Metab Dispos 34:880-6.
18. Perrett HF, Barter ZE, Jones BC, et al. (2007). Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos 35:1733-6.
19. Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-23.
20. Takeuchi F, McGinnis R, Bourgeois S, et al. (2009). A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5: e1000433.
21. Uehara S, Murayama N, Nakanishi Y, et al. (2014). Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica 44:769-74.
22. Uehara S, Murayama N, Nakanishi Y, et al. (2011). Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654-61.
23. Uno Y, Hosaka S, Matsuno K, et al. (2007). Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 466:98-105.
24. Uno Y, Iwasaki K, Yamazaki H, Nelson DR. (2011a). Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 43:346-61.
25. Uno Y, Matsuno K, Nakamura C, et al. (2011b). Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. J Vet Med Sci 73:487-90.
26. Uno Y, Matsushita A, Osada N, et al. (2010). Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos 38:209-14.
27. Uno Y, Osada N. (2011). CpG site degeneration triggered by the loss of functional constraint created a highly polymorphic macaque drug-metabolizing gene, CYP1A2. BMC Evol Biol 11:283.
28. Uno Y, Sakuraba H, Uehara S, et al. (2009). A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism. Drug Metab Dispos 37:14-17.
29. Wang MZ, Wu JQ, Bridges AS, et al. (2007). Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafurami-dine. Drug Metab Dispos 35:2067-75.
30. Wu S, Moomaw CR, Tomer KB, et al. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-8.
31. Yamazaki H, Okayama A, Imai N, et al. (2006). Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 36:1201-9.